Savage Medical, Inc. (“SavageMed”, “Firm”, “We”, or “Us”), a San Francisco Bay Space-based, clinical-stage medical expertise firm enabling minimally invasive colorectal tumor elimination, as we speak introduced a launch out of stealth with over $3 million in complete funding, together with oversubscribed financing from main early-stage medical expertise buyers together with Synergy Ventures, Life Science Angels and AlwaysraiseVC. Capital raised contributes to SavageMed’s ongoing scientific trial of its groundbreaking ColoSeal™ System. SavageMed’s ColoSeal™ has been efficiently examined in human scientific trials with constructive outcomes.
“In the present day, surgical procedure for colorectal tumors ceaselessly requires as much as 3 surgical procedures to take away the tumor and keep away from the unwanted effects of the tumor elimination, together with the dreaded want for a short lived ostomy bag,” mentioned Ankit Sarin, M.D., M.H.A., Chief, Division of Colorectal Surgical procedure, Vice Chair of Robotics & New Applied sciences, Division of Surgical procedure, UC Davis Well being. “ColoSeal permits a one-time, minimally invasive process after the tumor elimination that doubtlessly eliminates the necessity for the extra surgical procedures and avoids want for an ostomy.”
“Yearly, there are 1.9 million folks recognized with colorectal most cancers. 35% of those sufferers have localized tumors which require surgical procedure to take away,” mentioned Kenton Fong, M.D., Chief Government Officer of Savage Medical, Inc. “We’re thrilled to shut this newest financing to proceed advancing the ColoSeal System by scientific trials. Our imaginative and prescient is to switch the a number of surgical procedures and issues that lots of of hundreds of colorectal sufferers endure every year with a minimally invasive resolution.”